Clinical trials: Pregnancy, Multiple
Herpes Genitalis
An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.
The aim of this study is to assess performance of using healthcare tools to understand genital Herpes Simplex Virus-2 (HSV-2) in patients ≥ 18 years of age in the United States and Europe.
- Trial name
- NCT04950712
- Testing
- Blood sampling, Anogenital lesion swab collection
- Where
- 51 sites in United States, Finland and 4 more
- Volunteers
- 537 people
- Sponsor
- GlaxoSmithKline
Kidney Stone
Trial of Efficacy of the RetroPerc Device
The purpose of this study is to determine the efficacy of RetroPerc® in obtaining renal access for percutaneous nephrolithotomy
- Trial name
- NCT05022537
- Testing
- retrograde nephrostomy, antegrade nephrostomy
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate.
- Conditions
- Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
- Trial name
- RESPOND-2 (NCT06933472)
- Testing
- AP301, AP301 Low Dose
- Where
- 42 sites in United States, China
- Volunteers
- 264 people
- Sponsor
- Alebund Pharmaceuticals
Bladder Cancer
Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
This is a multicenter, single-arm study to evaluate the efficacy and safety of Pseudomonas aeruginosa the treatment of patients with intermediate and high risk non-muscle invasive bladder cancer.
- Trial name
- NCT05975151
- Testing
- Pseudomonas aeruginosa
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Qilu Hospital of Shandong University
Human Papillomavirus
Multi-site HPV Screening by High-throughput Sequencing in Patients With Chronic HPV-HR Infection Followed by Gynecology
The main risk of developing cervical cancer is the persistence of an High risk human papillomavirus (HPV-HR) infection, the mechanisms of which are still not understood.
- Trial name
- DEP-HPV (NCT04901351)
- Testing
- Smear
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Renal Impairment, Renal Disease
Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects
This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with renal impairment and healthy adults.
- Conditions
- Renal Impairment, Renal Disease, Kidney Disease
- Trial name
- NCT05368935
- Testing
- Nitazoxanide
- Where
- 2 sites in United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Genfit
Diabetic Nephropathies
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)
This study will be conducted in Japanese subjects with type 2 diabetes mellitus and the clinical diagnosis of Diabetic Nephropathy( DN) using a multi-center, randomized, adaptive, double-blind, placebo-controlled, parallel-group…
- Trial name
- NCT01968668
- Testing
- BAY94-8862, BAY 94-8862
- Where
- 16 sites in Japan
- Volunteers
- 96 people
- Sponsor
- Bayer
Sickle Cell Disease
Oxygen Therapy and Pregnancy in Sickle Cell Disease
The purpose of this study is to assess the efficiency of the preventive oxygen therapy on the occurrence of vaso-occlusive complications, which last more than 24 hours and require hospitalisation, in women with sickle cell…
- Trial name
- DRO2G (NCT02813850)
- Testing
- oxygen therapy
- Where
- France
- Volunteers
- 178 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Out-of-Hospital Cardiac Arrest
AMCPR (Augmented-Medication CardioPulmonary Resuscitation) Trial for OHCA
The investigators aimed to evaluate the effect of AMCPR (Augmented-Medication CardioPulmonary Resuscitation: administration of additional vasopressin to titrate to arterial diastolic blood pressure over 20 mmHg) on…
- Trial name
- NCT03191240
- Testing
- Vasopressins, Normal saline
- Where
- 2 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- Asan Medical Center
Anemia, Iron Deficiency
Co-administration of Calcium and Multiple Micronutrient Supplements for Maternal and Newborn Hemoglobin and Iron Status
The World Health Organization (WHO) currently recommends the pregnant women receive iron-containing supplements and, in settings where calcium intake is low, calcium supplements.
- Trial name
- CaMMS (NCT06568315)
- Testing
- Concurrent multiple micronutrient and calcium supplementation, Separate multiple micronutrient and calcium supplementation
- Where
- 2 sites in Burkina Faso, Pakistan
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Respiratory Syncytial Virus Infections
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
The purpose of this follow-up study was to describe the safety in subsequent pregnancies in participants who were previously administered the RSVPreF3 maternal vaccine or control during any prior RSV MAT study.
- Trial name
- NCT05705440
- Testing
- RSVPreF3 vaccine, Control
- Where
- 138 sites in United States, Argentina and 21 more
- Volunteers
- 3,855 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
A Study of AZD4901 in Females With Polycystic Ovary Syndrome
To assess the effects of AZD4901 when given in multiple doses to females with Polycystic Ovary Syndrome
- Trial name
- NCT01872078
- Testing
- AZD4901 (oral)
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Polycystic Ovary Syndrome, Obesity
Correlating Improvement in PCOS Symptoms to the Percentage of Body Weight Lost in Females Also Living With Obesity
The goal of this clinical trial is to study the effects of a intensive weight loss program (STREAM) in patients living with PCOS.
- Trial name
- FLOWERS-PCOS (NCT06325449)
- Testing
- STREAM program
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Bladder Cancer
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
The purpose of this study is to explore a treatment that potentially enhances the delivery of chemotherapy to tumors in participants with superficial bladder cancer.
- Trial name
- NCT00318643
- Testing
- Mitomycin C, Chemophase
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Halozyme Therapeutics
Muscle Invasive Bladder Cancer
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
- Trial name
- NIAGARA (NCT03732677)
- Testing
- Durvalumab, Cisplatin, Gemcitabine
- Where
- 188 sites in United States, Australia and 20 more
- Volunteers
- 1,063 people
- Sponsor
- AstraZeneca
Urinary Bladder Neoplasms
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
- Trial name
- SunRISe-4 (NCT04919512)
- Testing
- TAR-200, Cetrelimab
- Where
- 109 sites in United States, Belgium and 8 more
- Volunteers
- 163 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Sclerosis, Pregnancy
Kesimpta (Ofatumumab) Pregnancy Registry
The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.
- Trial name
- NCT05634967
- Testing
- Kesimpta
- Where
- United States
- Volunteers
- 725 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
In this study, researchers will learn more about the effects of diroximel fumarate (DRF), also known as VUMERITY®, when taken during pregnancy in people with multiple sclerosis, also known as MS.
- Trial name
- NCT05688436
- Testing
- Diroximel Fumarate, Alemtuzumab, Fingolimod
- Where
- United States
- Volunteers
- 1,178 people
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.